SummaryChronic kidney disease (CKD) is defined as an abnormality of kidney structure or function that persists for > 3 months. The most common causes of CKD in the United States are diabetes mellitus, hypertension, and glomerulonephritis. The kidney's efficient compensatory mechanisms and significant renal reserve mean that most patients remain asymptomatic until their kidney function is severely impaired. While patients are most commonly initially identified because of gradual asymptomatic elevation in serum creatinine, at advanced disease stages, patients may present with symptoms of fluid overload (e.g., peripheral edema) and/or uremia (e.g., fatigue, pruritus). Patients with CKD also have a significantly increased risk of developing atherosclerotic cardiovascular disease (ASCVD). Laboratory studies may show metabolic complications, such as hyperkalemia, hyperphosphatemia, hypocalcemia, and metabolic acidosis. The goal of management is to slow CKD progression and prevent and manage complications. This includes treatment of the underlying disease, avoiding nephrotoxic substances, maintaining adequate hydration and nutrition, reducing ASCVD risk (e.g., using statin therapy and adequate treatment of high blood pressure and/or diabetes), and addressing complications such as anemia of chronic kidney disease and CKD-mineral and bone disorder. Renal replacement therapy (i.e., dialysis or kidney transplantation) is required if CKD progresses to end-stage renal disease (ESRD). Show
See also “Acute kidney injury” (AKI). Epidemiology
Epidemiological data refers to the US, unless otherwise specified. Etiology
PathophysiologyPathophysiology depends on the underlying condition, any of which will eventually lead to progressive nephron loss, structural damage, and impaired kidney function. Underlying conditions
Consequences
Clinical featuresPatients are often asymptomatic until later stages due to the exceptional compensatory mechanisms of the kidneys. Manifestations of Na+/H2O retention
Manifestations of uremia
Kidney OUTAGES: hyperKalemia, renal Osteodystrophy, Uremia, Triglyceridemia, Acidosis (metabolic), Growth delay, Erythropoietin deficiency (anemia), Sodium/water retention (consequences of chronic kidney disease) Diagnostic criteria and classificationDiagnostic criteria [5]
CKD is classified according to the cause, eGFR category, and albuminuria category; this is referred to as the CGA classification. Cause [5]
eGFR and albuminuria [5]DiagnosticsThe goals of the diagnostic evaluation include confirming the chronicity of kidney dysfunction and identifying the cause of kidney disease. The diagnosis of CKD requires the persistence of eGFR < 60 mL/min/1.73 m2 and/or of a marker of kidney damage for more than 3 months. A rapid rise in creatinine level (i.e., over days rather than weeks or months), recent onset of uremia, and/or oliguria or anuria suggest AKI (with or without underlying CKD). Initial laboratory studiesParameters of renal function
Urine studies
If the UPCR is significantly higher than the UACR, plasma cell dyscrasia should be suspected. Send a urine sample for protein electrophoresis to identify urine proteins other than albumin (e.g., Bence Jones protein). Ultrasound of the kidneys and urinary tract
Consider obtaining an ultrasound of the kidneys and urinary tract as part of the routine evaluation of all patients with CKD. Additional investigations should be considered based on clinical suspicion or if an underlying cause of CKD is not apparent following an initial assessment. Integration of information from the patient's clinical presentation, laboratory tests, imaging, and in some cases, pathology, is needed to determine the underlying cause. Noninvasive testingRenal biopsy [5][14]Renal biopsy is only indicated in patients in whom the underlying cause of CKD is still unclear after noninvasive testing, the results are likely to influence management, and the potential benefits are thought to outweigh the risks. ManagementThe following guidance applies to patients with CKD category G1–G5 who are not on dialysis and have not had a kidney transplant. The goals of treatment are to delay the progression of CKD and prevent and manage complications. If CKD progression or complications are detected during follow-up, review the current management and assess for reversible causes of progression (e.g., nephrotoxin exposure, medications affecting glomerular perfusion, urinary tract obstruction). Pay attention to the prevention of AKI, as this may further compromise kidney function. If there are indications for acute dialysis, urgently initiate renal replacement therapy. Nutritional management [15]
Dietary protein restriction must ONLY be prescribed under close clinical supervision and in consultation with a nutritionist. Obtain a nutritionist consult for all patients with CKD. Patients with CKD are at an increased risk of vaccine-preventable infections. Patients with CKD may be immunocompromised. Decisions regarding the use of live vaccines should therefore take into account the patient's current immune status and be made in consultation with a specialist. [5] Medication management [5][14]
Weigh the risks and benefits of potentially nephrotoxic substances on a case-by-case basis. Given the increased risk of AKI in acutely ill patients with CKD, consider temporarily holding renally cleared medications and medications that can detrimentally affect glomerular perfusion (e.g., NSAIDs, ACEIs, ARBs). Renal replacement therapy [5]
Monitoring and management of ASCVD risk factorsSpecific recommendations for ASCVD risk management in patients with CKD are reviewed below; see also “Hypertension,” “Lipid disorders,” “Diabetes,” and “ASCVD.” ASCVD risk assessmentManagement of ASCVD risk not only reduces cardiovascular morbidity and mortality, but also helps prevent CKD progression. Cardiovascular disease (e.g., coronary artery disease, stroke) is the leading cause of death in patients with CKD. The risk of cardiovascular events is higher in patients with more advanced stages of CKD. [5] Blood pressure control [17]
Avoid any combination of an ACEI, ARB, and/or direct renin inhibitor because of the increased risk of hyperkalemia and AKI. Good blood pressure control is essential to prevent ASCVD complications, reduce mortality, and help delay disease progression in patients with CKD. Lipid management [18][19]
For patients with eGFR < 60 mL/min/1.73 m2 (eGFR category G3–G5), adjustments to the recommended statin doses are required to reduce their potential for toxicity. Statin therapy may be indicated regardless of serum lipid levels, as patients with CKD have a higher ASCVD risk than the general population. Individuals with CKD often have dyslipidemia (e.g., ↑ triglycerides, ↑ LDL, ↓ HDL) due to alterations in lipoprotein metabolism. SGLT-2 inhibitors and GLP-1 receptor agonists have been shown to slow CKD progression and reduce urinary albumin excretion and ASCVD events. [20][22] In patients with CKD category G4–G5 who were previously on metformin and/or an SGLT-2 inhibitor, metformin should be discontinued; the SGLT-2 inhibitor may be continued if tolerated. Monitoring for complicationsIn CKD, close surveillance of serum potassium, calcium, and phosphate levels is essential. Screening and periodic monitoring for complications are indicated in all patients with CKD and eGFR < 60 mL/min/1.73 m2. ComplicationsFor recommendations on screening tests and frequencies, see “Monitoring for complications.” Specialist consultation (e.g., with a nephrologist) is advised for the management of complications. Maintain a low threshold for suspecting infections and initiating empiric antibiotics, as signs of sepsis may be vague or absent in patients with CKD. [25][28] Anemia of chronic kidney disease [5][29][30]
ManagementTreatment with ESAs is not recommended for patients with Hb levels ≥ 10 g/dL because their use has been associated with increased mortality, stroke, and venous thromboembolism. Chronic kidney disease-mineral and bone disorder (CKD-MBD) [31][32]
Hyperphosphatemia, hypocalcemia, and insufficient production of vitamin D in patients with CKD may lead to secondary hyperparathyroidism and consequent renal osteodystrophy. Growth delay and developmental delay in childrenWe list the most important complications. The selection is not exhaustive. Special patient groupsRelated One-Minute TelegramInterested in the newest medical research, distilled down to just one minute? Sign up for the One-Minute Telegram in “Tips and links” below. References
Which of the following would likely cause chronic renal failure?The most common causes of chronic renal failure in North America are diabetes mellitus (type 1 or type 2 diabetes) and high blood pressure. One of the complications resulting from diabetes or high blood pressure is the damage to the small blood vessels in the body.
Which clinical indicators would the nurse expect for a client who has end stage renal disease ESRD )?These include fatigue, drowsiness, decrease in urination or inability to urinate, dry skin, itchy skin, headache, weight loss, nausea, bone pain, skin and nail changes and easy bruising. Doctors can diagnose the disease with blood tests, urine tests, kidney ultrasound, kidney biopsy, and CT scan.
Why does chronic glomerulonephritis cause renal failure?Glomerulonephritis (GN) is inflammation of the glomeruli, which are structures in your kidneys that are made up of tiny blood vessels. These knots of vessels help filter your blood and remove excess fluids. If your glomeruli are damaged, your kidneys will stop working properly, and you can go into kidney failure.
Under what circumstances do cells in the kidneys secrete renin?Hormones The kidneys secrete a number of hormones, which are important for normal functioning of the body. One such hormone is renin, which keeps blood pressure normal. If blood pressure falls, renin is secreted by the kidneys to constrict the small blood vessels, thereby increasing blood pressure.
|